Evaluating long-term safety and effectiveness of growth hormone in children with various conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the long-term safety and effectiveness of growth hormone treatment in children diagnosed with Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age, and Idiopathic Short Stature. The study will involve children aged 2 years or older who meet the inclusion criteria and have received informed consent from their guardians. By monitoring these children over time, the study seeks to gather valuable data on the outcomes of growth hormone therapy in these specific populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* short stature children aged 2 years or more
* children with GHD,TS, CRF, SGA or ISS
* written informed consent from the person, person's parent or legal guardian

Where it's running

• Seoul National University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: HW Chae, M.D. — Kangnam severance hospital
• Study coordinator: YoungHwan Jang
• Email: younghj@lgls.com
• Phone: 82-2-6924-3158

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating the long-term safety and effectiveness of Growtropin®-II in children with short stature

  This study is testing whether the Growtropin®-II treatment is safe and effective for children with short stature caused by various conditions, to see how it helps them grow and stay healthy over time.

  Recruiting Dong-A ST Co., Ltd. · Seoul, Seodaemun-gu · NCT04798690

• Once-weekly lonapegsomatropin versus daily somatropin for children and adolescents with short stature due to growth-hormone-sufficient conditions

  It will test whether a once-weekly injection of lonapegsomatropin helps children and teens with Turner syndrome, SHOX mutation, small-for-gestational-age, or idiopathic short stature grow as well as or better than daily somatropin.

  Recruiting at 56 sites Phase 3 Ascendis Pharma A/S · Phoenix, Arizona and 55 other locations · NCT07221851

• Nurse-led programs mixing exercise and psychology to help people with chronic kidney disease

  This study tests whether a nurse-led program that combines physical exercise and psychosocial support can improve outcomes for adults with chronic renal failure on dialysis or in hospital.

  Recruiting Menoufia University · Shibīn al Kawm, Menoufia · NCT07927660

• Long-term Inpegsomatropin Treatment for Idiopathic Short Stature: Extension of Phase III Study

  This extension study tests whether continuing Inpegsomatropin injections helps kids with Idiopathic Short Stature who finished a prior phase 3 trial.

  Recruiting at 27 sites Xiamen Amoytop Biotech Co., Ltd. · Beijing and 26 other locations · NCT07894341

• Understanding growth hormone deficiency after a brain injury in adults

  This observational study tests whether growth hormone deficiency affects quality of life and symptoms in adults with traumatic brain injury and whether GH replacement helps after 12 weeks.

  Recruiting University of Calgary · Calgary, Alberta and 1 other locations · NCT07795736

• Inpegsomatropin vs Givopegsomatropin for short stature in girls with Turner syndrome

  A 52-week, multicenter, randomized study tests whether Inpegsomatropin injections help prepubertal girls with Turner syndrome grow taller compared with a known treatment.

  Recruiting at 49 sites Phase 3 Xiamen Amoytop Biotech Co., Ltd. · Anyang and 50 other locations · NCT07614152

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.